As of 2025-07-10, the Intrinsic Value of Simcere Pharmaceutical Group Ltd (2096.HK) is 6.99 HKD. This 2096.HK valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 10.70 HKD, the upside of Simcere Pharmaceutical Group Ltd is -34.60%.
The range of the Intrinsic Value is 5.49 - 9.99 HKD
Based on its market price of 10.70 HKD and our intrinsic valuation, Simcere Pharmaceutical Group Ltd (2096.HK) is overvalued by 34.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 5.49 - 9.99 | 6.99 | -34.6% |
| DCF (Growth 10y) | 7.79 - 14.12 | 9.92 | -7.3% |
| DCF (EBITDA 5y) | 9.36 - 16.81 | 12.36 | 15.5% |
| DCF (EBITDA 10y) | 10.26 - 18.46 | 13.49 | 26.1% |
| Fair Value | 2.13 - 2.13 | 2.13 | -80.11% |
| P/E | 6.87 - 9.21 | 8.06 | -24.7% |
| EV/EBITDA | 5.22 - 11.58 | 8.89 | -16.9% |
| EPV | 1.35 - 1.63 | 1.49 | -86.1% |
| DDM - Stable | 2.49 - 6.31 | 4.40 | -58.8% |
| DDM - Multi | 4.69 - 8.79 | 6.07 | -43.3% |
| Market Cap (mil) | 26,603.62 |
| Beta | 0.59 |
| Outstanding shares (mil) | 2,486.32 |
| Enterprise Value (mil) | 25,799.82 |
| Market risk premium | 5.98% |
| Cost of Equity | 10.34% |
| Cost of Debt | 4.25% |
| WACC | 10.04% |